CAMERA: COMBINATION ANTIBIOTIC TREATMENT FOR METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS BACTERAEMIA - A RANDOMISED CONTROLLED TRIAL
Grant number: 1078930 | Funding period: 2015 - 2019
MRSA (golden staph) is resistant to the most useful class of antibiotics: beta-lactams. It is more difficult to treat than antibiotic-sensitive strains. Standard treatment for MRSA is vancomycin but it has high failure rates. Although MRSA is resistant to beta-lactams, lab studies show that they enhance vancomycin’s bacterial killing when used together. CAMERA2 is an RCT comparing vancomycin alone to combination therapy (vancomycin plus flucloxacillin) for adults with MRSA blood stream infection
Related publications (2)
Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal beta-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia A Randomized Clinical Trial
Steven YC Tong, David C Lye, Dafna Yahav, Archana Sud, J Owen Robinson, Jane Nelson, Sophia Archuleta, Matthew A Roberts, Alan Cass, David L Paterson, Hong Foo, Mical Paul, Stephen D Guy, Adrian R Tramontana, Genevieve B Walls, Stephen McBride, Narin Bak, Niladri Ghosh, Benjamin A Rogers, Anna P Ralph
IMPORTANCE: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with mortality of more than 20%. Combining..
CAMERA2-combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial
Steven YC Tong, Jane Nelson, David L Paterson, Vance G Fowler, Benjamin P Howden, Allen C Cheng, Mark Chatfield, Jeffrey Lipman, Sebastian Van Hal, Matthew O'Sullivan, James O Robinson, Dafna Yahav, David Lye, Joshua S Davis
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is a serious infection resulting in 20-50 % 90-day mort..